Diphtheria toxoid carrier protein (CRM197)

The diphtheria toxoid carrier protein is an inactivated and non-toxic derivative of diphtheria toxin used as a carrier in protein-polysaccharide conjugate vaccines, such as those for *Haemophilus influenzae* type b, *Streptococcus pneumoniae*, and *Neisseria meningitidis*[2][7][5]. The CRM197 variant, produced by a single point mutation (G52E), retains structural similarity to the wild-type toxin but lacks catalytic activity and toxicity, making it ideal for clinical application as a vaccine antigen carrier[2][7]. The protein provides abundant T-helper epitopes, converting polysaccharide antigens into T-cell–dependent immunogens, enabling robust, long-lasting, and memory-based immune responses—capabilities that pure polysaccharides lack. Its widespread use has been critical to the success of pediatric conjugate vaccines worldwide. Structural integrity (notably conserved disulfide bonds) is crucial for its immunogenic function in conjugate vaccines[4][9]. The protein is not itself pathogenic or a drug target in the conventional sense, but is essential for vaccine technology as a "carrier protein" to enhance the immunogenicity of otherwise weak antigens[5][2][7]. Methods to chemically conjugate polysaccharides to CRM197 are a focus of ongoing research and optimization, as disruptions in the protein structure can negatively impact vaccine efficacy[4][9].

Other names

CRM197Diphtheria toxin mutant CRM197Diphtheria toxoidDiphtheria toxin G52E mutant

Provides multiple T-helper epitopes, enabling protein-polysaccharide conjugate vaccines to elicit a robust, T-cell–dependent, long-lasting IgG antibody response against poorly immunogenic polysaccharide antigens[5][8]. Facilitates isotype switching in B cells and the generation of immunological memory